What Is the Drug Advertising Act in Germany (HWG)? 2026 Guide for Rx vs OTC, Social Media & BGH Cannabis Ruling

Understanding what is the drug advertising act in Germany is now mission-critical for every pharma, medtech and telehealth team operating in the country. The Heilmittelwerbegesetz (HWG) governs how medicines, medical devices and therapeutic treatments may be promoted, and 2026 has sharpened its teeth. On 26 March 2026, the Federal Court of Justice (BGH) confirmed that advertising medical cannabis treatments to consumers violates the HWG’s prescription-medicine advertising ban (Case I ZR 74/25). At the same time, regulators and competitors are scrutinising influencer marketing and social media disclosures in Germany with growing intensity, creating new enforcement risks for digital channels.

What this guide covers:

• HWG statutory framework, scope, definitions and interaction with EU law
• Rx vs OTC advertising rules, a channel-by-channel comparison table
• HWG §10 public advertising ban, statutory text, interpretation and common traps
• BGH 26 March 2026 ruling, case facts, holding and practical implications for medical cannabis advertising in Germany 2026
• Social media and influencer compliance, disclosure templates and platform mechanics
• Enforcement, penalties and UWG interplay, risk matrix and remedies
• Nine-step pre-publication compliance checklist

What Is the Heilmittelwerbegesetz (HWG)? Scope and Structure

The Heilmittelwerbegesetz (HWG) is Germany’s primary statute regulating advertising of medicinal products, medical devices, cosmetics and therapeutic treatments. Its overriding purpose is consumer protection: preventing misleading or dangerous health claims from reaching the public and ensuring that promotional communications about medicines remain accurate, balanced and appropriately targeted.

Key HWG Definitions

The HWG applies to any person or entity that disseminates advertising for covered products, manufacturers, marketing-authorisation holders, distributors, healthcare providers, pharmacies and, critically, online platforms and influencers acting on their behalf. The statute distinguishes between two audiences:

• Fachkreise (professional circles): Physicians, pharmacists, veterinarians and other healthcare professionals who are permitted to receive detailed product information, including clinical data and off-label study references, provided the content is not misleading.
• Laien (lay public / consumers): Any communication directed at the general public is subject to stricter controls, including an absolute prohibition on public advertising for prescription-only (Rx) medicines under HWG §10.

The term “advertising” (Werbung) is interpreted broadly. It covers traditional media, digital channels, sponsored content, patient testimonials used in a promotional context, and, as the BGH confirmed in 2026, internet portals that market doctor-led treatments with named prescription products.

How the HWG Interacts with EU Law and the Medicinal Products Act

The HWG does not exist in isolation. At EU level, Directive 2001/83/EC on the advertising of medicinal products for human use sets baseline requirements that all member states must implement. Germany’s HWG transposes these EU provisions into national law, often with additional strictness. The German Medicinal Products Act (Arzneimittelgesetz, AMG) defines which substances qualify as medicinal products and thus fall within HWG scope. Where a product is classified as a medicinal product under the AMG, all HWG advertising restrictions automatically apply, a point the BGH underscored in its March 2026 cannabis ruling.

For companies operating across EU borders, the practical effect is that pharmaceutical advertising in Germany must satisfy both the EU-level restrictions and the more granular national HWG requirements. The EUR-Lex summary of Directive 2001/83/EC confirms that direct-to-consumer advertising of prescription medicines is prohibited across the EU; the HWG implements this ban through §10.

Rx vs OTC, What Is Allowed and What Is Banned Under the Drug Advertising Act in Germany

The most consequential distinction in the HWG is between prescription-only medicines (Rx) and over-the-counter products (OTC). For compliance teams, the rule is straightforward in principle but nuanced in practice: Rx products may never be advertised to the public; OTC products may be promoted to consumers provided the content is accurate, balanced and includes mandatory disclosures.

Practical Examples Across Print, Web and Broadcast

A pharmaceutical company may run a television advertisement for an OTC cold remedy, provided it includes the mandatory disclaimer: “Zu Risiken und Nebenwirkungen lesen Sie die Packungsbeilage und fragen Sie Ihren Arzt oder Apotheker” (For risks and side effects, read the package leaflet and ask your doctor or pharmacist). The same company may not run a consumer-facing social media campaign naming a prescription antibiotic, even if the post also contains a risk disclosure.

For digital channels, the boundary between permissible informational content and prohibited advertising is often contested. Industry observers expect that borderline cases, such as telehealth platforms listing specific Rx treatments alongside appointment-booking functionality, will face increasing scrutiny following the BGH’s 2026 reasoning.

HWG §10 Public Advertising Ban, Statutory Text and Interpretation

HWG §10 is the centrepiece of Germany’s prescription-medicine advertising regime. It prohibits advertising of prescription-only medicinal products outside professional circles. The provision targets any communication that is designed to promote the sale, prescription or use of an Rx product and that reaches the general public.

The ban covers explicit product promotion and extends to indirect methods: mentioning a prescription product by name in a consumer-facing context that is designed to generate demand can trigger a violation, even if the communication also contains factual or educational content. Claims must not be misleading, must reference only approved indications and must not suggest efficacy beyond what the Summary of Product Characteristics (SmPC) supports.

Common Compliance Traps

• Pre-approval promotion. Advertising a medicinal product before marketing authorisation is granted violates both the HWG and the AMG. This includes teaser campaigns that reference a product by code name or anticipated brand name.
• Off-label mentions. Referring to uses not covered by the approved indications, even when supported by emerging clinical evidence, constitutes a prohibited claim when directed at consumers. Within Fachkreise communications, off-label references are more permissible but must be clearly labelled.
• Comparative claims. Stating that a product is superior to a competitor’s without robust clinical evidence risks both an HWG violation and a challenge under the Unfair Competition Act (UWG).
• Disguised advertising. Sponsored content, native advertising and paid influencer posts that fail to identify their commercial nature breach general advertising-transparency requirements and, when involving Rx products, compound an HWG §10 violation.

BGH 26 March 2026, Medical Cannabis Advertising Decision (I ZR 74/25)

The Federal Court of Justice’s judgment of 26 March 2026 (Case I ZR 74/25) is the defining ruling on medical cannabis advertising in Germany 2026. The BGH clarified that advertising prescription-only medical cannabis treatments to consumers remains prohibited under the HWG, regardless of the partial legalisation of recreational cannabis under the Konsumcannabisgesetz (KCanG) that took effect on 1 April 2024.

The case concerned an internet portal that offered doctor-led telemedicine consultations for medical cannabis prescriptions and advertised these services directly to consumers. The portal promoted specific treatment pathways using prescription medical cannabis, including appointment booking and streamlined prescription processes. A competitor brought proceedings under unfair-competition law, arguing that the portal’s consumer-facing advertising violated the HWG §10 prohibition.

The BGH agreed. In its reasoning, the court held that medical cannabis, whether as dried flowers or extracts, remains a prescription-only medicinal product under the AMG. The partial recreational legalisation under the KCanG did not change the regulatory classification of medical cannabis for therapeutic purposes. Therefore, the HWG’s prohibition on advertising prescription medicines to the public applies in full.

What the Ruling Prohibits, and What Remains Permissible

The BGH’s decision draws a clear line:

• Prohibited: Consumer-facing advertising that promotes doctor consultations specifically for medical cannabis prescriptions, names medical cannabis products, or creates an expectation that consumers can conveniently obtain prescriptions through a particular platform.
• Permissible: Purely factual information about telemedicine services that does not reference specific prescription products; professional-to-professional communications about medical cannabis treatment options; unbranded disease-awareness content that does not steer consumers toward a particular prescription solution.

The likely practical effect for telehealth platforms and online cannabis clinics will be significant. Early indications suggest that platforms will need to restructure their consumer-facing content to remove references to specific Rx treatments and instead limit public messaging to general service descriptions. The ruling also creates precedent that industry observers expect competitors and consumer-protection bodies to apply against other telemedicine portals advertising prescription treatments directly to patients.

Social Media, Influencer Marketing and Telehealth, Disclosures and Compliance Mechanics

The intersection of influencer marketing, pharma and Germany’s advertising laws creates one of the most active compliance risk areas in 2026. Social media disclosures in Germany must satisfy both the HWG and general advertising-transparency rules under the UWG and the Telemediengesetz (TMG). For pharmaceutical advertising in Germany, the stakes are particularly high: a single influencer post naming an Rx product can trigger competitor cease-and-desist proceedings within days.

Practical Disclosure Templates

The following templates illustrate compliance-safe approaches for common scenarios in influencer marketing pharma Germany:

• Disease-awareness post (unbranded, Rx-adjacent): “Paid partnership with [Company]. This post discusses [condition]. It does not promote any specific medicine. Consult your doctor for treatment options.”, Do not name any prescription product. Do not link to a specific treatment booking page.
• OTC product promotion: “Ad | #Anzeige, [OTC product name]. For risks and side effects, read the package leaflet and ask your doctor or pharmacist.”, Include the mandatory German-language disclaimer. Ensure all efficacy claims match the approved label.
• Telehealth platform listing (what to avoid): Do not state: “Book your medical cannabis consultation now.” Instead, permissible language is limited to: “We offer telemedicine appointments with licensed physicians”, with no reference to specific Rx products or treatment pathways.

Platform Mechanics, Ad Labelling, Archiving and Audit Trails

Compliance does not stop at copy. Teams must implement platform-level controls:

• Ad labelling: Use native platform tools (Instagram “Paid partnership” tag, YouTube “Includes paid promotion” checkbox) in addition to text-based disclosures (#Anzeige, #Werbung). Both layers are recommended to satisfy German transparency standards.
• Pinned disclosures: On platforms where posts scroll (TikTok, Instagram Stories), pin the disclosure so it is visible without user interaction for the entire duration of the content.
• Archiving for audit: Save screenshots, URLs and metadata for every sponsored post. Retain records for a minimum of three years. Ensure contracts with influencers include a clause granting access to post analytics and archival copies.

Enforcement, Penalties and Interplay with the Unfair Competition Act (UWG)

Germany’s enforcement landscape for pharmaceutical advertising violations is distinctive because it relies heavily on private enforcement. Under the Gesetz gegen den unlauteren Wettbewerb (UWG), the Unfair Competition Act Germany, competitors, trade associations and qualified consumer-protection bodies can bring civil claims directly against advertisers. This means that HWG breaches are most commonly pursued through competitor-initiated cease-and-desist letters (Abmahnungen) and injunction proceedings, not through regulatory fines.

The typical enforcement sequence involves a formal warning letter demanding cessation and a penalty-backed undertaking (strafbewehrte Unterlassungserklärung), followed by court proceedings if the advertiser does not comply. Successful claims can result in injunctions, damages for lost revenue, and recovery of legal costs, all borne by the infringing party. In serious cases involving deliberate or reckless violations, criminal liability under the HWG or the AMG may also apply.

Risk Matrix

Compliance Playbook, Pre-Publication Checklist for the Drug Advertising Act in Germany

The following nine-step checklist translates HWG and UWG obligations into a practical workflow that regulatory, legal and marketing teams can implement before any promotional content goes live.

1. Classify the product. Determine whether the product is Rx, OTC, a medical device or a cosmetic. This dictates which HWG provisions apply.
2. Identify the target audience. Is the content directed at Fachkreise (professionals) or the lay public? Rx advertising is only permissible for the former.
3. Map all claims to the SmPC or approved label. Every efficacy, safety or indication claim must be traceable to the approved Summary of Product Characteristics.
4. Draft compliant copy. Include all mandatory disclaimers. For OTC consumer advertising, insert the standard risk-disclosure statement.
5. Legal and regulatory review. Route all content through internal medical-legal review before approval. Flag comparative claims, off-label references and influencer briefs for elevated scrutiny.
6. Insert influencer contract clauses. Require disclosure compliance (#Anzeige / Paid partnership), prohibit Rx product mentions, mandate pre-approval of all draft posts and grant audit access.
7. Implement platform-level controls. Activate native ad-labelling tools, pin disclosures and archive all published content with timestamps.
8. Establish a monitoring and escalation protocol. Assign a compliance officer to monitor live content weekly. Escalate any flagged posts to legal within 24 hours.
9. Maintain audit logs. Retain copies of all approved content, reviewer sign-offs, influencer contracts and monitoring reports for a minimum of three years.

Templates and SOP Snippets

• Content sign-off flow: Marketing drafts → Medical-legal review → Regulatory sign-off → Compliance archive → Publish.
• Sample influencer contract clause: “The Influencer shall not name, depict or reference any prescription-only medicinal product in any content produced under this agreement. All posts must include a prominent commercial-disclosure tag visible without user interaction.”
• Sample monitoring language: “The Compliance Officer shall review all sponsored social media posts within 48 hours of publication and document findings in the quarterly audit log.”

Conclusion

Understanding what is the drug advertising act in Germany, and how its provisions interact with the UWG, EU directives and the BGH’s March 2026 medical cannabis decision, is essential for any organisation marketing health products in the German market. The rules are precise, enforcement is competitor-driven and consequences are immediate. Teams that invest in a structured compliance workflow, from product classification through influencer contract clauses to post-publication monitoring, can reduce legal risk while maintaining effective market presence. For tailored guidance on HWG compliance, find a Germany Life Sciences lawyer through our directory.

Sources

1. Bundesgerichtshof, Case Page I ZR 74/25
2. SKW Schwarz, Client Alert on BGH Decision
3. Bundesgesundheitsministerium, Medicinal Products Act (English PDF)
4. EUR-Lex, Advertising of Medicinal Products for Human Use
5. ICLG, Pharmaceutical Advertising Laws (Germany)
6. CMS Expert Guide, Germany Advertising of Medicines and Medical Devices
7. NCBI / PMC, Analysis of HWG
8. Osborne Clarke, BGH Advertising Case Analysis
9. HANF-Magazin, BGH Effects on Cannabis Advertising
10. Diekmann Rechtsanwälte, German Drug Advertising Practice